Basic Information
Briviact (in Italy: Nubriveo)
Regulatory Information
EMEA/H/C/003898
January 13, 2016
25
December 3, 2024
Company Information
Belgium
Allée de la Recherche 60 1070 Bruxelles
UCB PHARMA SA
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Overview Summary
Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain). It can be used in patients from the age of 2 years with partial-onset seizures with or without secondary generalisation (where the abnormal electrical activity spreads through the brain). Briviact contains the active substance brivaracetam.